Status:
TERMINATED
Propranolol in Capillary Hemangiomas
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Hemangioma, Capillary
Eligibility:
All Genders
Up to 4 years
Phase:
PHASE2
PHASE3
Brief Summary
The investigators observed that Propranolol, a beta-blocker commonly used in children was efficient to control the growth of alarming hemangiomas of the face. The primary objective of this study is t...
Detailed Description
Infantile hemangiomas are frequent vascular tumors (4 à 10 % of the neonates) and correspond to 100 new cases per year in dermatology consultation of the CHU of Bordeaux. Hemangiomas have a characteri...
Eligibility Criteria
Inclusion
- Infant aged less than 4 months
- Infant with one or more hemangiomas sized more than 1 cm diameter
- Infant not threatening for vital or functional structure and for which no treatment would be proposed
- Informed consent
- Patient with social insurance.
Exclusion
- Alarming hemangioma (s) (complicated forms or localization at risk)
- Cardiac pathology (cardiac malformation, heart failure, cardiac arrhythmias, pulmonary hypertension)
- Asthma
- Bronchopulmonary dysplasia
- Bronchiolitis
- Raynaud syndrome
- Phéochromocytoma
- Development of serious form of hemangioma (bleeding, necrosis, ulceration, infection, respiratory distress) requiring standard treatment
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00744185
Start Date
October 1 2008
End Date
April 1 2010
Last Update
July 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatologie Pédiatrique
Bordeaux, France, 33 076